Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00502086
Status:
COMPLETED
Last Update Posted:
2011-02-11
First Post:
2007-07-13
Brief Title:
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection
Sponsor:
Catalysis SL
Organization:
Catalysis SL
Study Overview
Official Title:
Efficacy and Safety of Viusid a Nutritional Supplement in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection A Randomized Controlled and Double Blind Study
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate whether Viusid a nutritional supplement reduce the mortality and the complications ascites spontaneous bacterial peritonitis hepatorenal syndrome hepatic encephalopathy gastrointestinal bleeding sepsis and hepatocellular carcinoma of patients with cirrhosis of the liver secondary to HCV infection in comparison with placebo during 96 weeks of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None